Treatment Outcomes Associated with Dupilumab Use in Patients with Atopic Dermatitis: 1-Year Results from the RELIEVE-AD Study

Treatment Outcomes Associated with Dupilumab Use in Patients with Atopic Dermatitis: 1-Year Results from the RELIEVE-AD Study

Importance: Clinical trial populations may not reflect clinical practice: knowledge generated in other settings can inform clinical decision-making. Objective: To evaluate self-reported disease control and quality of life after initiating dupilumab treatment in patients with atopic dermatitis (AD) i...

Full description

Bibliographic Details
Main Authors: Delevry, D. (Author), Gadkari, A. (Author), Ganguli, S. (Author), Kimball, A.B (Author), Mallya, U.G (Author), Sierka, D. (Author), Strober, B. (Author), Wang, J. (Author), Yang, M. (Author)
Format: Article
Language:English
Published: American Medical Association 2022
Subjects:
adult
Adult
Antibodies, Monoclonal, Humanized
atopic dermatitis
cohort analysis
Cohort Studies
Dermatitis, Atopic
double blind procedure
Double-Blind Method
dupilumab
female
Female
human
Humans
monoclonal antibody
quality of life
Quality of Life
severity of illness index
Severity of Illness Index
treatment outcome
Treatment Outcome
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items